Zhong Zhao
Vorstandsvorsitzender bei ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
Vermögen: 130 Mio $ am 30.04.2024
Aktive Positionen von Zhong Zhao
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. | Vorstandsvorsitzender | 06.11.2012 | - |
| Vorsitzender | 06.11.2012 | - | |
| Gründer | 06.11.2012 | - | |
| AVINGER, INC. | Direktor/Vorstandsmitglied | 05.03.2024 | - |
| Independent Dir/Board Member | 05.03.2024 | - |
Karriereverlauf von Zhong Zhao
Ehemalige bekannte Positionen von Zhong Zhao
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Cordis Corp.
 Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | Corporate Officer/Principal | 01.07.2002 | 01.08.2011 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | 01.07.1996 | 01.06.2002 |
Ausbildung von Zhong Zhao
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| China | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
| Chairman | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. | Health Technology |
| AVINGER, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | Health Technology |
- Börse
- Insiders
- Zhong Zhao
- Erfahrung
